Lunit, a medical artificial intelligence (AI) company, announced on Thursday that it will present 21 of its latest research findings at the European Congress of Radiology (ECR 2026), scheduled for April 4-8 in Vienna, Austria.

The conference will showcase studies evaluating the clinical value of Lunit's AI-powered solutions: Lunit INSIGHT MMG for mammography analysis, Scorecard for breast density quantification, and Lunit INSIGHT CXR for chest X-ray analysis.

Of the 21 accepted research abstracts, 13 will be featured in oral presentations, while 8 will be presented as posters.

A key study to be unveiled at ECR 2026 focuses on early breast cancer risk assessment, conducted by Dr. Claudia Weiss's team from AULSS n.2 Marca Trevigiana in Treviso, Italy.

The researchers analyzed mammography data from 67,686 women to determine if risk scores generated by Lunit INSIGHT MMG could identify women initially cleared but at higher risk of developing breast cancer later.

Lunit will also present research on AI's potential in interval cancer detection. A team led by Professor Yan Chen from the University of Nottingham evaluated AI's feasibility in the NHS Breast Screening Programme's (NHSBSP) classification procedures.

Results from a large-scale randomized controlled trial using Lunit International Ltd.'s (formerly Volpara) Scorecard breast density quantification solution will also be revealed.

Dr. Carla van Gils's team from the University Medical Center Utrecht investigated whether additional magnetic resonance imaging (MRI) screenings for women with extremely dense breasts, as classified by Scorecard, could reduce advanced breast cancer incidence among those with initial negative mammography results.

Seo Bum-suk, Chief Executive Officer (CEO) of Lunit, stated that these studies demonstrate AI's potential in early risk assessment, screening quality control, and high-risk group identification. It'll continue building clinical evidence for global screening practices through collaborations with leading medical institutions worldwide.

Lunit, a medical artificial intelligence (AI) company, announced on Thursday that it will …

How Lunit's AI is Transforming Early Breast Cancer Risk Assessment: Key Findings from ECR 2026